Evidence map›Paper›PMID 37530955›Full record

ArticleJournal of thrombosis and thrombolysis2024

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.

Brett D Atwater, Jennifer D Guo, Allison Keshishian, Rachel Delinger, Cristina Russ, Lisa Rosenblatt, Jenny Jiang, Huseyin Yuce, Mauricio Ferri

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Brett D AtwaterInova Heart and Vascular Institute, 4Th Floor Medical Directors Suite, 3300 Gallows Road, Falls Church, VA, 22042, USA. brett.atwater@inova.org.
Jennifer D GuoBristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Allison KeshishianSTATinMED, LLC, Ann Arbor, MI, USA.
Rachel DelingerSTATinMED, LLC, Ann Arbor, MI, USA.
Cristina RussPfizer Inc., New York, NY, USA.
Lisa RosenblattBristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Jenny JiangBristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Huseyin YuceNew York City College of Technology, City University of New York, New York, NY, USA.
Mauricio FerriBristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Bristol-Myers Squibb (United States) · USSTATinMED (United States) · USCity University of New York · USInova Health System · USPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOral anticoagulants effectively prevent stroke/systemic embolism among patients with non-valvular atrial fibrillation but remain under-prescribed. This study evaluated temporal trends in oral anticoagulant use, the incidence of stroke/systemic embolism and major bleeding, and economic outcomes among elderly patients with non-valvular atrial fibrillation and CHA

methodsRetrospective analyses were conducted on Medicare claims data from January 1, 2012 through December 31, 2017. Non-valvular atrial fibrillation patients aged ≥ 65 years with CHA

resultsBaseline patient characteristics remained generally similar between 2013 and 2016. Although lack of oral anticoagulant prescriptions among eligible patients remained relatively high, utilization did increase progressively (53-58%). Among treated patients, there was a progressive decrease in warfarin use (79-52%) and a progressive increase in overall direct oral anticoagulant use (21-48%). There were progressive decreases in the incidence of stroke/systemic embolism 1.9-1.4 events per 100 person years) and major bleeding (4.6-3.3 events per 100 person years) as well as all-cause costs between 2013 and 2016.

conclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.

Indexed as

Atrial FibrillationEmbolismStrokeAdministration, OralAgedAnticoagulantsHealth Care CostsHemorrhageHumansMedicareRetrospective StudiesUnited StatesAnticoagulantsAtrial fibrillationDirect oral anticoagulantMajor bleedingStroke/systemic embolism

Identifiers

PMID37530955
PMCPMC10830709
OpenAlexW4385477171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.